ESA REMS Allows Oncology Providers One Year To Enroll Before Possible Distribution Limits
This article was originally published in The Pink Sheet Daily
Executive Summary
The Risk Evaluation and Mitigation Strategy for erythropoiesis-stimulating agents announced by FDA Feb. 16 focuses on requiring health care providers to educate patients about the risks and benefits of treatment.